Samantha D. Le
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Samantha D. Le has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jerod S. Denton
Vanderbilt University
3 shared publications Kangjun Li
Vanderbilt University
3 shared publicationsRoman M. Lazarenko
Vanderbilt University Medical Center
2 shared publicationsVaishali Satpute Janve
Vanderbilt University Medical Center
2 shared publications- Alex G. Waterson
Vanderbilt University
1 shared publication - Alican Gulsevin
Department of Chemistry, Vanderbilt University Nashville
1 shared publication
Latest Publications
- Open Access
- 1 December 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (6) , C1607-C1615
TMEM175: lysosomal ion channel physiology, therapeutic potential, and emerging pharmacology
Transmembrane protein 175 (TMEM175) is a lysosomal cation channel that has emerged as a promising drug target for Parkinson’s disease (PD). Genetic and functional studies linking TMEM175 loss-of-function variants to increased PD risk, lysosomal dysfunction, and α-synuclein accumulation have generated considerable interest in developing pharmacological approaches to enhance channel activity. As a lysosomal cation channel with reported K + and H + permeability, TMEM175 regulates lysosomal membrane potential, pH stability, autophagic flux, and degradative capacity, placing it at a critical control point for cellular proteostasis. Recent advances in high-throughput screening, automated and lysosomal patch clamp electrophysiology, cryoelectron microscopy, and structure-guided medicinal chemistry have transformed TMEM175 from a relatively obscure lysosomal ion channel into a tractable drug target. These approaches have enabled the discovery of multiple classes of TMEM175 modulators while providing new insights into channel gating and mechanisms of activation. In this review, we summarize current progress in TMEM175 pharmacology, including advances in functional assay development and the emerging landscape of tool compounds used to study channel function. We discuss TMEM175 physiology and structure-function relationships, the growing evidence supporting therapeutic intervention, and recent discoveries revealing multiple mechanisms of channel activation. Finally, we highlight key challenges that remain for the field, including the development of potent and selective modulators, opportunities afforded by synergistic channel activation, and the potential application of TMEM175-directed therapeutics beyond Parkinson’s disease in a broader range of neurodegenerative and lysosome-associated disorders.
- 1 December 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (6) , C1607-C1615
Open AccessTMEM175: lysosomal ion channel physiology, therapeutic potential, and emerging pharmacology
Transmembrane protein 175 (TMEM175) is a lysosomal cation channel that has emerged as a promising drug target for Parkinson’s disease (PD). Genetic and functional studies linking TMEM175 loss-of-function variants to increased PD risk, lysosomal dysfunction, and α-synuclein accumulation have generated considerable interest in developing pharmacological approaches to enhance channel activity. As a lysosomal cation channel with reported K + and H + permeability, TMEM175 regulates lysosomal membrane potential, pH stability, autophagic flux, and degradative capacity, placing it at a critical control point for cellular proteostasis. Recent advances in high-throughput screening, automated and lysosomal patch clamp electrophysiology, cryoelectron microscopy, and structure-guided medicinal chemistry have transformed TMEM175 from a relatively obscure lysosomal ion channel into a tractable drug target. These approaches have enabled the discovery of multiple classes of TMEM175 modulators while providing new insights into channel gating and mechanisms of activation. In this review, we summarize current progress in TMEM175 pharmacology, including advances in functional assay development and the emerging landscape of tool compounds used to study channel function. We discuss TMEM175 physiology and structure-function relationships, the growing evidence supporting therapeutic intervention, and recent discoveries revealing multiple mechanisms of channel activation. Finally, we highlight key challenges that remain for the field, including the development of potent and selective modulators, opportunities afforded by synergistic channel activation, and the potential application of TMEM175-directed therapeutics beyond Parkinson’s disease in a broader range of neurodegenerative and lysosome-associated disorders.
- 2 July 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (2) , C415-C424
A non-hydrolyzable candesartan cilexetil analog reveals synergistic activation as a tractable mechanism for TMEM175 modulation
TMEM175 is a lysosomal cation channel essential for maintaining lysosomal pH and function. Dysregulation of TMEM175 has been implicated in Parkinson’s disease, highlighting the need for small-molecule modulators to probe its physiological and therapeutic roles. We previously screened an FDA approved compound library for TMEM175 modulators using a plasma membrane overexpression system that enables functional analysis of channel activity. Here, we report the pharmacological characterization of the most potent hit, candesartan cilexetil. In fluorescence-based thallium flux, automated patch-clamp, and manual patch-clamp assays, candesartan cilexetil robustly activates TMEM175 with efficacy comparable to the reference activator DCPIB, whereas its hydrolyzed metabolite candesartan is inactive. Candesartan cilexetil is active only when applied to the extracellular (lysosome lumen–equivalent) side of the channel and is inactive from the cytosolic-facing side. To determine whether activation requires the intact prodrug, we generated analogs that modify or eliminate the cilexetil and ester functionalities. Structure–activity studies show that selected modifications of the cilexetil moiety reduce potency while preserving maximal efficacy, whereas more extensive modification markedly reduces intrinsic activity. , indicating that it is an essential pharmacophoric element rather than a simple membrane-permeating handle. Manual patch-clamp wash-off experiments further demonstrate direct, reversible activation without requiring membrane permeation or hydrolysis. Unexpectedly, the non-hydrolyzable analog VU0982645 exhibits minimal intrinsic activity yet produces robust synergistic activation with DCPIB. Together, these findings establish the cilexetil handle as a key pharmacophoric element and support synergistic modulation as a tractable mechanism for activating TMEM175.
- 2 July 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (2) , C415-C424
A non-hydrolyzable candesartan cilexetil analog reveals synergistic activation as a tractable mechanism for TMEM175 modulation
TMEM175 is a lysosomal cation channel essential for maintaining lysosomal pH and function. Dysregulation of TMEM175 has been implicated in Parkinson’s disease, highlighting the need for small-molecule modulators to probe its physiological and therapeutic roles. We previously screened an FDA approved compound library for TMEM175 modulators using a plasma membrane overexpression system that enables functional analysis of channel activity. Here, we report the pharmacological characterization of the most potent hit, candesartan cilexetil. In fluorescence-based thallium flux, automated patch-clamp, and manual patch-clamp assays, candesartan cilexetil robustly activates TMEM175 with efficacy comparable to the reference activator DCPIB, whereas its hydrolyzed metabolite candesartan is inactive. Candesartan cilexetil is active only when applied to the extracellular (lysosome lumen–equivalent) side of the channel and is inactive from the cytosolic-facing side. To determine whether activation requires the intact prodrug, we generated analogs that modify or eliminate the cilexetil and ester functionalities. Structure–activity studies show that selected modifications of the cilexetil moiety reduce potency while preserving maximal efficacy, whereas more extensive modification markedly reduces intrinsic activity. , indicating that it is an essential pharmacophoric element rather than a simple membrane-permeating handle. Manual patch-clamp wash-off experiments further demonstrate direct, reversible activation without requiring membrane permeation or hydrolysis. Unexpectedly, the non-hydrolyzable analog VU0982645 exhibits minimal intrinsic activity yet produces robust synergistic activation with DCPIB. Together, these findings establish the cilexetil handle as a key pharmacophoric element and support synergistic modulation as a tractable mechanism for activating TMEM175.
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 330 (4) , C715-C726
Activation of TMEM175 lysosomal ion channels by CysLT1 receptor antagonists
TMEM175 regulates lysosomal voltage and pH and is genetically linked to Parkinson’s disease. Our study identifies zafirlukast and related drugs as activators, defines their AKT dependency, and maps structural determinants of gating. These results open new avenues for targeting TMEM175 in neurodegenerative diseases.
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 330 (4) , C715-C726
Activation of TMEM175 lysosomal ion channels by CysLT1 receptor antagonists
TMEM175 regulates lysosomal voltage and pH and is genetically linked to Parkinson’s disease. Our study identifies zafirlukast and related drugs as activators, defines their AKT dependency, and maps structural determinants of gating. These results open new avenues for targeting TMEM175 in neurodegenerative diseases.